Results from the KEYNOTE-522 trial showed that adding pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased the rates of pathologic complete response (pCR) in patients with stage 3 and/or node-positive early triple-negative breast cancer. The benefit of neoadjuvant pembrolizumab + chemotherapy on pCR was also observed in patients who received less than the planned chemotherapy (although absolute pCR rates were lower), and regardless of combined positive score threshold.
Results from the phase 1b KEYNOTE-173 and the phase 2 I-SPY 2 studies already demonstrated that the combination of pembrolizumab with chemotherapy as neoadjuvant treatment had manageable side effects and promising anti-tumour activity in patients with locally advanced triple-negative breast cancer [1,2]. The phase 3 KEYNOTE-522 study assessed pembrolizumab + chemotherapy (n=401) versus placebo + chemotherapy (n=201) as neoadjuvant therapy, followed by pembrolizumab versus plac...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients Next Article
Breast cancer incidence decreased by oestrogen alone but increased by adding progestin »
Table of Contents: SABCS 2019
Screening, Detection, and Diagnosis
Phase 2 Trial Update
Phase 3 Trial Update
Long-Term Study Results
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.